Brainsway

BrainsWay to Report First Quarter 2024 Financial Results on May 8, 2024

Retrieved on: 
Wednesday, April 24, 2024
Brainsway, Conference, Webcast

BURLINGTON, Mass.

Key Points: 
  • BURLINGTON, Mass.
  • and JERUSALEM, April 24, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Wednesday, May 8, 2024.
  • The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
  • Conference Call Dial-In & Webcast Information:

BrainsWay Expands Deep TMS™ Access in Israel Following Significant Increase in Reimbursement Rates

Retrieved on: 
Wednesday, April 17, 2024
Brainsway, Transcranial magnetic stimulation, Business development, Mental health, Patient, Nursing

and JERUSALEM, April 17, 2024 (GLOBE NEWSWIRE) --  BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the further expansion of access to its Deep TMS™ treatment in Israel.

Key Points: 
  • and JERUSALEM, April 17, 2024 (GLOBE NEWSWIRE) --  BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the further expansion of access to its Deep TMS™ treatment in Israel.
  • BrainsWay has steadily increased its presence in the country with 11 recent system installations, and this momentum has been driven in part by a 45% increase in reimbursement rates.
  • The Company expects to have additional Deep TMS systems installed in Israel by the end of 2024.
  • “We are excited to bring Deep TMS to those suffering from mental health conditions who are truly in need of additional treatment solutions."

BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's Disease

Retrieved on: 
Thursday, April 4, 2024
Deep, Transcranial magnetic stimulation, Brainsway, Medicine, Parkinson's disease, PD, Patient, Research, Quality of life, FDA, Pharmaceutical industry

The paper was published in Frontiers of Human Neuroscience, a leading peer-reviewed journal focused on advancing the understanding of brain mechanisms in both healthy and diseased states.

Key Points: 
  • The paper was published in Frontiers of Human Neuroscience, a leading peer-reviewed journal focused on advancing the understanding of brain mechanisms in both healthy and diseased states.
  • The review summarizes data from six different studies involving an aggregate total of 220 patients, including a substantial number of patients who were administered a two-stage Deep TMS protocol addressing prefrontal and motor targets.
  • "This clinical review marks an important step forward in our understanding of the potential benefits of Deep TMS for those suffering from Parkinson's Disease,” said Colleen Hanlon, Ph.D., Vice President of Medical and Clinical Affairs at BrainsWay.
  • BrainsWay Deep TMS is not cleared by the FDA as a safe and/or effective treatment for Parkinson's Disease.

BrainsWay Announces Positive Results in Late-Life Depression Post-Marketing Analysis

Retrieved on: 
Thursday, March 28, 2024
Depression, Deep, Brainsway, Medicine, Safety, MDD, Patient, Ageing, TMS, Journal, Doctor of Philosophy, DSM-IV codes, Efficacy, Mixed anxiety–depressive disorder, Atrophy, Scalp, FDA, Pharmaceutical industry

The post-marketing study demonstrated real-world outcomes for older adults (60-91 years of age) suffering from major depressive disorder (MDD).

Key Points: 
  • The post-marketing study demonstrated real-world outcomes for older adults (60-91 years of age) suffering from major depressive disorder (MDD).
  • In the study, data was analyzed from 247 depression patients at 16 clinical sites in this age group who had been treated with BrainsWay’s proprietary H1 Coil.
  • The outcomes were comparable to those reported in a post-marketing analysis of over 1,350 patients published in 2023.
  • This can make it challenging for certain non-invasive technologies to reach the brain areas involved in depression,” said Colleen Hanlon, PhD, Vice President of Medical and Clinical Affairs at BrainsWay.

BrainsWay Broadens Partnership with Katie’s Way Plus Through Order of an Additional 18 Deep TMS™ Systems

Retrieved on: 
Monday, March 18, 2024
Depression, Deep, Transcranial magnetic stimulation, Brainsway, Prevalence, Veteran, Mental, Memory, Partnership, TMS, Acquisition, Hope, DSM-IV codes, Military personnel, Marketing, Suicide, Nursing

Katie’s Way Plus will now grow to an extensive network of approximately 40 Deep TMS systems.

Key Points: 
  • Katie’s Way Plus will now grow to an extensive network of approximately 40 Deep TMS systems.
  • “We are delighted to continue supporting Katie's Way Plus in its pivotal mission of delivering specialized care to U.S. service members, veterans, and their families,” said Chris Boyer, BrainsWay’s Vice President of Marketing.
  • “The efficacy demonstrated by BrainsWay's advanced Deep TMS technology in the treatment of depression is transformational.
  • In one study conducted across 27 states, it was found that the suicide rate among veterans is 50% higher than non-veterans1.

BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights

Retrieved on: 
Wednesday, March 6, 2024
TMS, Parkinson's disease, Medicine, Mental health, Human, Traction, Growth, Stroke, Adjustment, Safety, DSM-IV codes, Tic disorder, Mixed anxiety–depressive disorder, Brainsway, Journal, Rehabilitation, Science, OCD, Transcranial magnetic stimulation

BURLINGTON, Mass. and JERUSALEM, March 06, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported fourth quarter and full-year 2023 financial results and provided an operational update.

Key Points: 
  • and JERUSALEM, March 06, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported fourth quarter and full-year 2023 financial results and provided an operational update.
  • Gross margin for the fourth quarter of 2023 was 75%, an increase from 71% in the fourth quarter of 2022, and an increase from 74% in the third quarter of 2023.
  • Net income for the fourth quarter of 2023 was $0.1 million, compared to a net loss of $3.9 million for the fourth quarter of 2022, and a loss of $0.2 million for the third quarter of 2023.
  • Adjusted EBITDA1 for the fourth quarter of 2023 was approximately $0.8 million, compared to a loss of $3.6 million for the fourth quarter of 2022, and positive Adjusted EBITDA1 of $0.3 million in the third quarter of 2023.

BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

Retrieved on: 
Wednesday, February 21, 2024
Conference, Webcast, Brainsway

BURLINGTON, Mass.

Key Points: 
  • BURLINGTON, Mass.
  • and JERUSALEM, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its fourth quarter and full year 2023 financial results as well as operational highlights before the open of the U.S. financial markets on Wednesday, March 6, 2024.
  • The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
  • Conference Call Dial-In & Webcast Information:

BrainsWay Initiates Clinical Evaluation of Rotational Field “Deep TMS 360°™” Technology

Retrieved on: 
Wednesday, January 10, 2024
Patient, Tic disorder, TMS, Neuron, Rehabilitation, Stroke, Deep, Brainsway, OCD, Safety, FDA, Brain, Area studies, Pharmaceutical industry

The studies both involve BrainsWay’s exclusive, patented “Rotational Field” TMS (or “Deep TMS 360°™”), which employs a method of stimulation that enables activation of a greater number of neurons in the brain.

Key Points: 
  • The studies both involve BrainsWay’s exclusive, patented “Rotational Field” TMS (or “Deep TMS 360°™”), which employs a method of stimulation that enables activation of a greater number of neurons in the brain.
  • With the new Rotational Field system now being evaluated, two orthogonal TMS coils are placed perpendicular to each other and are operated with a time lag in order to induce a circularly rotating electric field.
  • The Company now aims to assess the potential clinical impact of this technology on patients in two newly launched feasibility studies.
  • “We believe that our Rotational Field technology holds significant potential to change the current TMS paradigm.

BrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. Network

Retrieved on: 
Tuesday, December 19, 2023
Partnership, Depression, FDA, Tic disorder, Deep, OCD, TMS, DSM-IV codes, Brain, Transcranial magnetic stimulation, Brainsway, Mental health, Pharmaceutical industry

and JERUSALEM, Dec. 19, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced increased collaboration with a growing mental health treatment provider based in the Western region of the United States.

Key Points: 
  • and JERUSALEM, Dec. 19, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced increased collaboration with a growing mental health treatment provider based in the Western region of the United States.
  • After a series of successive orders, BrainsWay’s most recent delivery will bring this provider’s installed base to a total of seven Deep Transcranial Magnetic Stimulation ( Deep TMS™) systems, with plans for additional expansion in the future.
  • By pulsing a magnetic field that targets affected structures of the brain, the Deep TMS system is capable of stimulating underactive or inactive neural networks.
  • The system is currently FDA-cleared to treat major depressive disorder both with and without anxiety symptoms, obsessive-compulsive disorder (OCD), and smoking addiction.

BrainsWay Announces Continued Expansion of Deep TMS™ in South Korea

Retrieved on: 
Thursday, December 7, 2023
Mental health, Patient, Deep, Health, TMS, DSM-IV codes, Brain, Transcranial magnetic stimulation, Brainsway, Traction

and JERUSALEM, Dec. 07, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced expanded availability of its Deep Transcranial Magnetic Stimulation (Deep TMS™) technology in South Korea.

Key Points: 
  • and JERUSALEM, Dec. 07, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced expanded availability of its Deep Transcranial Magnetic Stimulation (Deep TMS™) technology in South Korea.
  • After growing momentum over the past few years, recent sales are expected to bring BrainsWay’s installed base in the country to over 20 Deep TMS systems.
  • “I am pleased that our state-of-the-art technology is gaining increasing traction in South Korea, where it is already having a positive impact on mental health patients,” said Hadar Levy, Chief Executive Officer of BrainsWay.
  • BrainsWay’s unique therapeutic solution is currently cleared in South Korea to treat major depressive disorder.